CNBC's Seema Mody reports on some highs in the biotechnology sector.
Some strategists forecast the group could see further upside as one popular exchange-traded fund just broke through a round-numbered level.
Picks of Steel
One of Stephanie Link's Picks Jumps 10 percent
Some of the names on the move ahead of the open.
These are the stocks posting the largest moves after the bell.
CNBC's Meg Tirrell reports the latest from the Vertex Pharmaceuticals earnings call. The "Fast Money" traders weigh in on trading the pharma and biotech space.
U.S. stock index futures pointed to a higher open on Tuesday as several large-cap companies reported better-than-expected quarterly results.
Samsung Bioepis has won regulatory approval for key biosimilar drug, the first time the company's product has been approved for U.S. use.
South Korea's Samsung Bioepis wins U.S. FDA nod for biosimilar of J&J's Remicade.
CNBC's Meg Tirrell discusses what healthcare investors should expect from the biotech sector. With the "Fast Money" traders.
Increases in the prices of drugs added $8.7 billion to 2016 net income for 28 companies analyzed, accounting for 100 percent of earnings growth last year.
Data covering the past five administrations show that Trump has enjoyed a relatively good, and surprising, market in his first 100 days.
Jim Cramer gave a dose of wisdom on a biotech company that is taking on the hemophilia space.
According to a filing from the U.S. Patent and Trademark Office, Forward Pharma has been interfering with Biogen.
Shares of Acorda were hit today after a District Court invalidated four patents for Ampyra, which represents 95 percent of the company's revenue. CNBC's Meg Tirrell reports.
CNBC's Meg Tirrell reports on the latest market action in the bio-tech sector.
The track record in drug development for Alzheimer's disease has been terrible: a success rate of less than 1 percent.
Jim Cramer identified one company with strong fundamentals that’s got the extra kicker of being an attractive takeover.
CNBC's Meg Tirrell reports on the victory for Biogen in its patent case over its Multiple Sclerosis drug.